Analyst Rating Update on Nektar Therapeutics (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) : 8 analysts are covering Nektar Therapeutics (NASDAQ:NKTR) and their average rating on the stock is 1.38, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. 1 more analyst has given the stock a Sell recommendation.

Nektar Therapeutics (NASDAQ:NKTR) : The consensus price target for Nektar Therapeutics (NASDAQ:NKTR) is $17.67 for the short term with a standard deviation of $2.42. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $20, however, the pessimist price target for the company is $14.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Nektar Therapeutics (NASDAQ:NKTR): stock turned positive on Tuesday. Though the stock opened at $13.58, the bulls momentum made the stock top out at $13.93 level for the day. The stock recorded a low of $13.535 and closed the trading day at $13.76, in the green by 2.76%. The total traded volume for the day was 1,069,733. The stock had closed at $13.39 in the previous days trading.

In an insider trading activity, The director, of Nektar Therapeutics, Chess Robert had unloaded 5,000 shares at $15.5 per share in a transaction on June 1, 2016. The total value of transaction was $77,500. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.